Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C
Hercules Capital (HTGC) entered into a $165 million financing agreement with Beren Therapeutics to support the potential commercial launch of adrabetadex. The facility consists of a $110 million senior-secured debt term loan and a $55 million royalty financing, providing Beren with non-dilutive capital ahead of its November 2026 FDA decision.
Key figures
- Deal Value Usd
- 165000000
- Royalty cap
- 1.75x
- Initial draw
- 30000000
- Equity portion
- 135000000
- Us royalty rate
- 7.5%
- Debt facility size
- 110000000
- Non us royalty rate
- 5%
- Total beren financing
- 300000000
- Royalty financing size
- 55000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.